488 related articles for article (PubMed ID: 34462326)
1. CXCR6 is required for antitumor efficacy of intratumoral CD8
Wang B; Wang Y; Sun X; Deng G; Huang W; Wu X; Gu Y; Tian Z; Fan Z; Xu Q; Chen H; Sun Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462326
[TBL] [Abstract][Full Text] [Related]
2. CXCR6 deficiency impairs cancer vaccine efficacy and CD8
Karaki S; Blanc C; Tran T; Galy-Fauroux I; Mougel A; Dransart E; Anson M; Tanchot C; Paolini L; Gruel N; Gibault L; Lepimpec-Barhes F; Fabre E; Benhamouda N; Badoual C; Damotte D; Donnadieu E; Kobold S; Mami-Chouaib F; Golub R; Johannes L; Tartour E
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692218
[TBL] [Abstract][Full Text] [Related]
3. CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy.
Qu J; Wu B; Chen L; Wen Z; Fang L; Zheng J; Shen Q; Heng J; Zhou J; Zhou J
J Exp Clin Cancer Res; 2024 May; 43(1):134. PubMed ID: 38698468
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial immunotherapy induces tumor-infiltrating CD8
Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
6. CXCR6-Deficiency Improves the Control of Pulmonary
Ashhurst AS; Flórido M; Lin LCW; Quan D; Armitage E; Stifter SA; Stambas J; Britton WJ
Front Immunol; 2019; 10():339. PubMed ID: 30899256
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
8. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
[TBL] [Abstract][Full Text] [Related]
9. CXCR6 by increasing retention of memory CD8
Muthuswamy R; McGray AR; Battaglia S; He W; Miliotto A; Eppolito C; Matsuzaki J; Takemasa T; Koya R; Chodon T; Lichty BD; Shrikant P; Odunsi K
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607898
[TBL] [Abstract][Full Text] [Related]
10. CXCR6 expressing T cells: Functions and role in the control of tumors.
Mabrouk N; Tran T; Sam I; Pourmir I; Gruel N; Granier C; Pineau J; Gey A; Kobold S; Fabre E; Tartour E
Front Immunol; 2022; 13():1022136. PubMed ID: 36311728
[TBL] [Abstract][Full Text] [Related]
11. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models.
Onyshchenko K; Luo R; Rao X; Zhang X; Gaedicke S; Grosu AL; Firat E; Niedermann G
Theranostics; 2024; 14(6):2573-2588. PubMed ID: 38646638
[No Abstract] [Full Text] [Related]
13. Single-cell RNA transcriptome analysis of CNS immune cells reveals CXCL16/CXCR6 as maintenance factors for tissue-resident T cells that drive synapse elimination.
Rosen SF; Soung AL; Yang W; Ai S; Kanmogne M; Davé VA; Artyomov M; Magee JA; Klein RS
Genome Med; 2022 Sep; 14(1):108. PubMed ID: 36153630
[TBL] [Abstract][Full Text] [Related]
14. CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4
Mossanen JC; Kohlhepp M; Wehr A; Krenkel O; Liepelt A; Roeth AA; Möckel D; Heymann F; Lammers T; Gassler N; Hermann J; Jankowski J; Neumann UP; Luedde T; Trautwein C; Tacke F
Gastroenterology; 2019 May; 156(6):1877-1889.e4. PubMed ID: 30710528
[TBL] [Abstract][Full Text] [Related]
15. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
16. JAML promotes CD8 and γδ T cell antitumor immunity and is a novel target for cancer immunotherapy.
McGraw JM; Thelen F; Hampton EN; Bruno NE; Young TS; Havran WL; Witherden DA
J Exp Med; 2021 Oct; 218(10):. PubMed ID: 34427588
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.
Singh M; Vianden C; Cantwell MJ; Dai Z; Xiao Z; Sharma M; Khong H; Jaiswal AR; Faak F; Hailemichael Y; Janssen LME; Bharadwaj U; Curran MA; Diab A; Bassett RL; Tweardy DJ; Hwu P; Overwijk WW
Nat Commun; 2017 Nov; 8(1):1447. PubMed ID: 29129918
[TBL] [Abstract][Full Text] [Related]
20. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
Fujiwara K; Shigematsu K; Tachibana M; Okada N
IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
